Contents
Key findings
- 1Thymosin alpha-1 is a natural immune-signaling peptide; the drug version (thymalfasin, brand Zadaxin) is a lab-made copy used to modulate the immune system.
- 2It is one of the few peptides with real randomized human trials - most of the hype peptides have none.
- 3Meta-analyses of sepsis trials found lower short-term death rates with thymosin alpha-1, though many of those trials had quality limits.
- 4It is used and approved in 35+ countries for chronic hepatitis B; in the US it is not FDA-approved and holds only orphan-drug designation.
- 5"Immune boosting" claims sold online go well beyond what the trials tested - the real evidence is about specific, serious conditions.
Evidence level
Unusually for a peptide, thymosin alpha-1 has multiple randomized human trials and meta-analyses, mainly for sepsis and chronic hepatitis B. The evidence is real but has quality limits (many sepsis trials were single-blind), so we grade it promising rather than established.
Regulatory status
Thymosin alpha-1 is not FDA-approved in the United States - it holds only orphan-drug designation for a few conditions. It is approved and marketed as Zadaxin (thymalfasin) in more than 35 other countries, mainly for chronic hepatitis B.
Most peptides sold for "immune support" have no human trials at all. Thymosin alpha-1 is a genuine exception - it has real randomized studies, and it is an approved medicine in dozens of countries. That makes it one of the more interesting peptides to look at honestly, because for once there is actual evidence to weigh.
What thymosin alpha-1 is
Your body already makes thymosin alpha-1. It is a small protein (a peptide) released by the thymus, a gland that helps train your immune cells. It works as a signal that helps the immune system respond to infection and calm down when it should[1].
The drug version is a lab-made copy called thymalfasin, sold under the brand name Zadaxin. Unlike "boosting," what it does is better described as immune modulation - nudging an immune response toward a more balanced state, up or down depending on what is happening[1].
What it is actually used for
In the countries where it is approved, thymosin alpha-1 is used mainly for chronic hepatitis B, a long-term liver infection. It is given alongside or instead of other antiviral treatment to help the immune system control the virus[1].
It has also been studied - not necessarily approved - as an add-on treatment for sepsis (a life-threatening reaction to infection) and as a helper alongside treatment for certain cancers[1]. Those are serious, hospital-level conditions. That matters, because the "immune boosting for everyday wellness" pitch you see online is a long way from what the trials actually tested.
What the trials show
Sepsis. This is where thymosin alpha-1 has been studied most. A systematic review of randomized trials found that, pooled together, patients given thymosin alpha-1 had lower all-cause mortality than those who did not[2]. That is a meaningful signal. The honest caveat: many of those trials were small or single-blind (not fully blinded), which can inflate results.
The largest single trial, called ETASS, tested it in adults with severe sepsis. Its main result - fewer deaths at 28 days - did not quite reach statistical significance, though the direction pointed toward benefit and the authors called for bigger trials[3]. In plain terms: promising, not proven.
Hepatitis B. The reason it is approved in 35+ countries is a track record in chronic hepatitis B, where trials have shown it can help some patients gain better virus control[1].
Evidence versus approval - keep them separate
Here is the part that trips people up. Thymosin alpha-1 can be both "backed by real trials" and "not FDA-approved," at the same time, because those are two different things.
- Evidence: genuine randomized trials and meta-analyses exist (graded here as promising).
- US regulatory status: not FDA-approved. It holds only orphan-drug designation for a few conditions, which is an incentive for development - not a marketing approval[1]. Meanwhile it is a fully approved medicine abroad as Zadaxin.
So a product being sold in the US as "thymosin alpha-1" is not an FDA-approved drug, whatever the trial history in other countries.
What people say versus what is tested
Online, thymosin alpha-1 gets marketed for general "immune boosting," longevity, long-COVID, and more. Some of those are being studied, but studied is not the same as shown. The solid evidence is narrow and specific: hepatitis B, and a promising-but-unproven signal in sepsis. Everything past that is, for now, hope rather than data.
The bottom line
Thymosin alpha-1 is a real drug with a real evidence base - which already sets it apart from most peptides. But "real evidence" here means specific serious illnesses, mostly outside the US approval system, with trial-quality caveats. It is a genuinely interesting immune peptide. It is not the general-purpose wellness booster it is sold as.
Where to go next
- FDA-approved, off-label, investigational and unapproved peptides
- How to read peptide research
- Peptides vs SARMs: what's the difference, and which is safer?
- Immune research hub
Frequently asked questions
- What is thymosin alpha-1 used for?
- The drug version (thymalfasin, brand name Zadaxin) is used mainly to treat chronic hepatitis B in the many countries where it is approved. It has also been studied as an add-on immune treatment for sepsis and certain cancers.
- Is thymosin alpha-1 FDA-approved?
- No. It is not FDA-approved in the United States for any use - it holds only orphan-drug designation for a few conditions. It is approved and sold as Zadaxin in more than 35 other countries.
- Does thymosin alpha-1 boost your immune system?
- It modulates the immune system rather than simply 'boosting' it, and the real human evidence is about specific serious illnesses like hepatitis B and sepsis - not the general wellness 'immune boosting' it is often marketed for online.
- How strong is the evidence for thymosin alpha-1?
- Stronger than most peptides - it has genuine randomized trials and meta-analyses. But many of the sepsis trials had quality limits, and the largest US regulatory step is only orphan-drug status, so we grade the evidence promising, not established.
References
Numbered in order of first use. Study type is shown for every source; see our methodology for how we rank evidence.
- 1.
Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials Peer-reviewed review (PubMed 38308608), 2024.
Review
Result: Narrative review of thymosin alpha-1 across more than 30 human clinical trials (over 11,000 subjects), reporting it is generally well tolerated and used as an immune modulator in infections, sepsis, hepatitis and cancer; it is marketed internationally as thymalfasin (Zadaxin).
↑ back to text - 2.
The efficacy of thymosin alpha 1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials BMC Infectious Diseases (PMC5025565), 2016.
Systematic review
Result: Systematic review of randomized controlled trials of thymosin alpha-1 in sepsis; pooled analysis found lower all-cause mortality with thymosin alpha-1, while noting variable trial quality and calling for larger high-quality trials.
↑ back to text - 3.
The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial Critical Care (PMC4056079), 2013.
Randomized controlled trialAdults with severe sepsis in intensive caren = 361
Result: Multicenter, single-blind RCT of thymosin alpha-1 in severe sepsis. The reduction in 28-day mortality did not reach statistical significance in the primary analysis, though secondary analyses suggested possible benefit; the authors called for larger trials.
↑ back to text
Review status: Editorially reviewed against primary sources. This article was fact-checked against the primary sources listed in the references by our editorial team, and it has not been reviewed by a licensed clinician. It is educational content, not medical advice. Read our editorial policy and methodology. Spotted an error? Tell us.
